Isabella Strahan Completes Proton Therapy for Adolescent Medulloblastoma and Returns to College

Isabella experienced vomiting, headaches, and ataxia during her freshman year, leading to emergency resection of a cerebellar medulloblastoma. Treatment included four cycles of chemotherapy and proton craniospinal irradiation, chosen to limit dose to developing brain, cochlea, and heart. She has now returned to full-time coursework, a trajectory consistent with reports from specialized centers where five-year event-free survival for average-risk adolescent cases reaches 70-80 percent when multimodal therapy is delivered promptly.

Proton therapy data from prospective cohorts show measurable preservation of neurocognitive function and hearing compared with photon regimens, with one multi-institutional study reporting mean IQ decline of 1.5 points versus 5-7 points after conventional radiation. The Healthline account correctly notes this precision advantage but omits quantification of late endocrine and vascular risks that still require lifelong surveillance even after protons. Strahan’s advocacy link to St. Jude supplied immediate access to coordinated care, an advantage not available to most families.

Long-term follow-up must track secondary malignancies, growth hormone deficiency, and fertility, outcomes tracked in Children’s Oncology Group protocols but rarely discussed in media profiles. Isabella’s case illustrates how adolescent biology can differ from pediatric medulloblastoma, supporting referral to centers offering molecular subtyping and proton capability.

Next steps include serial MRI surveillance every three months for the first two years and annual neurocognitive testing to detect any delayed effects before they affect academic performance.